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ABSTRACT: This retrospective, multicentre study evaluated patients with lymphangioleiomyo-
matosis (LAM) and pre-capillary pulmonary hypertension (PH) by right heart catheterisation.
It was conducted in 20 females with a mean¡SD age of 49¡12 yrs and a mean¡SD time interval
between LAM and PH diagnoses of 9.2¡9.8 yrs. All, except for one patient, were receiving
supplemental oxygen. 6-min walking distance was mean¡SD 340¡84 m. Haemodynamic character-
istics were: mean pulmonary artery pressure (PAP) 32¡6 mmHg, cardiac index 3.5¡1.1 L?min-1?m-2
and pulmonary vascular resistance (PVR) 376¡184 dyn?s?cm-5. Mean PAP was .35 mmHg in only
20% of cases. The forced expiratory volume in 1 s was 42¡25%, carbon monoxide transfer factor
was 29¡13%, and arterial oxygen tension (Pa,O2) was 7.4¡1.3 kPa in room air. Mean PAP and PVR
did not correlate with Pa,O2. In six patients who received oral pulmonary arterial hypertension (PAH)
therapy, the PAP decreased from 33¡9 mmHg to 24¡10 mmHg and the PVR decreased from
481¡188 dyn?s?cm-5 to 280¡79 dyn?s?cm-5. The overall probability of survival was 94% at 2 yrs.
Pre-capillary PH of mild haemodynamic severity may occur in patients with LAM, even with mild
pulmonary function impairment. PAH therapy might improve the haemodynamics in PH associated
with LAM.
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L
ymphangioleiomyomatosis (LAM), a dis-
ease that mostly affects young and middle-
aged females [1–3], is characterised by the
proliferation of abnormal smooth muscle-like cells
(so-called LAM cells) along lymphatics in the lungs
and abdomen. Manifestations of LAM include:
diffuse cystic lung disease; recurrent pneu-
mothoraces; benign renal tumours (e.g. angiomyo-
lipomas); and lymphatic abnormalities, which
include pleural and peritoneal chylous effusion
as well as abdominal lymphangioleiomyomas.
Pulmonary involvement is dominated by the
formation and progression of thin-walled cysts,
the pathogenesis of which may implicate metallo-
protease secretion by LAM cells, leading to air-
flow obstruction, impairment of carbon monoxide
diffusion capacity, and chronic respiratory insuffi-
ciency [1–4]. Although sirolimus (a mammalian
target of rapamycin (mTOR) inhibitor) has recently
been demonstrated to slow the rate of lung
function decline [5], lung transplantation is the
sole treatment for LAM patients with advanced
disease [6–9]. Kaplan–Meier analysis estimated
transplantation-free survival to be ,80–90% at
10 yrs in a recent series of LAM patients [10, 11].
However, the rate of disease progression is highly
variable among patients [12–15].
Pulmonary hypertension (PH), which may occur
in LAM patients [16], is included in the PH group
with unclear and/or multifactorial mechanisms in
the Dana Point clinical classification of PH (group
5) [17]. Likely multifactorial [18] PH pathogenesis
in LAM patients is related, at least in part, to
hypoxia and reduced pulmonary vascular capaci-
tance caused by cystic lesions [19]. In addition,
mTOR expression is up-regulated in LAM [20],
and activation of mTOR complexes 1 and 2 is
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further enhanced by hypoxia, contributing to smooth muscle cell
proliferation [21] and conceivably to PH pathogenesis. TAVEIRA-
DASILVA et al. [19] reported 7% PH prevalence in 95 patients with
LAM, as defined by estimated systolic pulmonary artery pressure
(PAP) .35 mmHg on echocardiography. PH, confirmed by
right heart catheterisation (RHC) (mean PAP .25 mmHg), was
diagnosed in nine (45%) out of the 20 patients evaluated for lung
transplantation [7]. Little information is available regarding the
haemodynamic profile of PH in LAM, and there are no data on
the effect of pulmonary arterial hypertension (PAH)-specific
therapy, such as endothelin receptor antagonists, phosphodies-
terase type-5 inhibitors and prostacyclin derivatives.
This study aimed to: 1) evaluate by RHC the haemodynamic
characteristics of patients with LAM and PH not explained
otherwise; 2) determine whether haemodynamics may be
related to pulmonary function; 3) ascertain the survival of PH
patients with LAM; and 4) explore whether PH-specific therapy,
given off-label on an individual basis, can bring about
significant clinical and/or haemodynamic improvements.
PATIENTS AND METHODS
Study design
This multicentre study was undertaken by the French Reference
Centre for Rare Pulmonary Diseases (Lyon, France; coordinator
J-F. Cordier), the French Reference Centre for Pulmonary
Hypertension (Clamart, France; coordinator G. Simonneau), the
Centre for Rare Pulmonary Diseases (Milan, Italy; coordinator S
Harari), the Network of French Competence Centres for Rare
Pulmonary Diseases (Lyon, France; coordinator J-F. Cordier) and
Competence Centres for Pulmonary Hypertension (Clamart,
France; coordinator G. Simonneau), and the Groupe d’Etudes
et de Recherche sur les Maladies "Orphelines" Pulmonaires
(GERM"O"P), a collaborative group dedicated to research on rare
(so-called ‘‘orphan’’) pulmonary diseases. Participating physi-
cians prospectively reported all cases of LAM to the GERM"O"P
registry (coordinator J-F. Cordier). PH was screened by echocar-
diography at the discretion of the physicians; however, most
groups in France and Italy perform echocardiography once a
year in LAM patients with impaired lung function. RHC was
implemented in cases of suspected PH (with estimated systolic
PAP ofo40 mmHg on echocardiography) or evaluation for lung
transplantation.
Data on PH were collected prospectively from the Registry of the
French Network of Pulmonary Hypertension that now com-
prises of 24 university pulmonary vascular centres [22]. The
registry was opened in 2002 and enrolled all consecutive patients
aged o18 yrs with pre-capillary PH seen at these centres.
Additional results on LAM were obtained, retrospectively, and
data collection ended in December 2010. A control group of
patients with LAM (without PH) was obtained from the active
file of the centres. This study was compliant with the require-
ments of the Commission nationale de l’informatique et des
liberte´s (Paris, France) the organisation dedicated to privacy,
information technology, and civil rights in France. All patients
provided informed consent before participation [22]. The study
was approved by the Institutional Review Board of the French
Learned Society for Respiratory Medicine and registered at
www.clinicaltrials.gov (NCT00960895).
Inclusion criteria
The following inclusion criteria applied: 1) Definite or probable
LAM diagnosed according to European Respiratory Society
(ERS) recommendations [6]. 2) Pre-capillary PH, defined by
mean PAPo25 mmHg and pulmonary artery wedge pressure
f15 mmHg at RHC [23].
Patients with PAH, either idiopathic, heritable, or associated
with connective tissue diseases related to portal hypertension,
congenital heart disease, human immunodeficiency virus infec-
tion, or PH due to left heart disease or chronic thromboembolic
PH, were excluded. Chronic thromboembolic PH was ruled out
by ventilation perfusion scanning and high resolution computed
tomography (HRCT) of the chest. ‘‘Out-of-proportion’’ pre-
capillary PH was defined by mean PAP .35–40 mmHg.
Investigations
RHC was performed as described elsewhere [24] with values
obtained at end of expiration. Cardiac output was measured by
the standard thermodilution technique. A vasodilator test with
inhaled nitric oxide (10 ppm for 5–10 min) was carried out, and
positive acute responses were defined as a decrease in mean PAP
of .10 mmHg compared with baseline mean PAP (with mean
PAP ,40 mmHg), and normal or increased cardiac output [24].
Pulmonary function tests followed the joint guidelines of the
American Thoracic Society and the ERS [25–27]. Lung volume
was measured by whole-body plethysmography (Jaeger
Masterscreen Body1; Sebbac, Wuerzburg, Germany), and data
were expressed as percentages of predicted values [28]. A non-
encouraged 6-min walk test (6MWT) was performed according
to recommendations [29].
The date of PH diagnosis was defined as the date of RHC, and
all data (symptoms including New York Heart Association
(NYHA) functional class, 6MWT, pulmonary function, echo-
cardiography) were obtained within 2 months of RHC. PH
treatment was left to the physicians’ discretion, including the
management of pleural and other LAM manifestations, oxygen
supplementation as needed, oral anticoagulation, diuretics,
and possible PAH-specific therapy initiated after RHC.
Pathology
Explanted lungs of transplanted patients were reviewed by a
pathologist with particular expertise in pulmonary vascular
disease. The presence of LAM/perivascular epithelioid cells
(PEComa cells) was semi quantified as absent, mild, moderate,
or high, along cyst edges, alveolar walls, bronchioles, pul-
monary arteries, veins and lymphatics. Cells within the remo-
delled pulmonary arteries were further characterised by HMB45
immunostaining.
Statistical analysis
The data were analysed by Microsoft Excel 2003 and SPSS 17.0
(SSPS Inc., Chicago, IL, USA). All values were expressed as
mean¡SD. Correlations were calculated with Pearson’s correla-
tion coefficient. The probability of survival at each time-point was
estimated according to the Kaplan–Meier method, from the date
of the first haemodynamic evaluation demonstrating PH to the
end-point of death or censoring. All-cause mortality was included
in survival statistics. For overall survival calculation, transplanted
subjects were censored at the time of transplantation. Living
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patients were censored at the date of the last visit. Categorical data
were compared using the Fisher’s exact test. Haemodynamic and
pulmonary function variables were compared by the two-tailed
paired t-test. Statistical significance was established at p,0.05.
RESULTS
Patient population
29 LAM patients with suspected PH at echocardiography
underwent RHC. The estimated systolic PAP at echocardio-
graphy significantly correlated with the systolic PAP (r50.66,
p50.001) and with the mean PAP measured at RHC (r50.69,
p50.0006). The mean difference between the systolic PAP
estimated at echocardiography and the systolic PAP measured
at RHC was -5.4 mmHg (95% CI -13– -2 mmHg). The systolic
PAP at echocardiography was overestimated by o10 mmHg
when compared with RHC in four cases (14%), and was
underestimated by f10 mmHg in nine cases (31%). The
difference between the estimated systolic PAP at echocardio-
graphy and the measured systolic PAP at RHC was mainly
.10 mmHg in patients with a mean PAP ,25 mmHg (fig. 1).
Nine patients had mean PAP between 20 mmHg and
24 mmHg and were excluded from the subsequent analysis.
Thus, the study population comprised of 20 patients, including
18 with sporadic LAM and two with LAM associated with
tuberous sclerosis complex; all were female, with a mean age of
49¡12 yrs and not reported previously [7, 16]. In total, 270
LAM patients were included in the GERM‘‘O’’P registry
(n5222) or followed in the Milan referral centre (n548) during
the study period; therefore, it was estimated that PH patients
represented a minimum of 7% of LAM patients. The reasons
for RHC were evaluation for transplantation (n59) and/or
suspicion of PH based on systematic echocardiography (n511).
The baseline clinical data are reported in table 1. The diagnosis
of LAM was definitive in 19 patients, and probable in one
nonsmoker with characteristic chest imaging, obstructive ventila-
tory defect, and compatible medical history. A pattern character-
istic of LAM [6] was present on HRCT of the chest in all patients.
The diagnosis was confirmed by video-assisted thoracoscopic
lung biopsy in 13 cases (65%). 15 patients were ex-smokers, with a
median of 10 pack-yrs. One patient had a history of splenectomy
and another had taken anorexigens. One patient had undergone
unilateral nephrectomy for angiomyolipoma. When compared
with LAM patients without PH, patients with LAM and PH had
more severe dyspnoea and presented more frequently with right
heart failure or haemoptysis.
LAM was treated as follows: inhaled bronchodilators, 75% of
patients; progesterone derivatives and/or anti-oestrogen ther-
apy, 45%; doxycycline, 30%; sirolimus, 25%.
Clinical and functional evaluation
The mean time interval between LAM diagnosis and the first
RHC demonstrating PH was 9.2¡9.8 yrs (range 0–36 yrs), and
the mean time period between first respiratory symptoms and
PH was 10.4¡7.5 yrs (range 3.0–22.1 yrs). NYHA functional
class was III or IV in 95% of these patients.
Echocardiography revealed dilated right heart cardiac cavities
in seven (35%) out of 20 patients. The mean value of systolic
PAP estimated at echocardiography was 56¡18 mmHg (range
40–108). Mild pericardial effusion was reported in one patient.
B-type natriuretic peptide (BNP) level was normal in all of the
seven patients tested. Haemoglobin was .160 g?L-1 in two
patients (10%).
The 6-min walking distance (6MWD) was 340¡84 m, with mean
desaturation of 10¡8%. The median Borg index value of
dyspnoea at the end of the 6MWT, available in 11 patients, was
4 (range, 3–6). Table 2 presents the pulmonary function test
results. Obstructive ventilatory defect, defined by forced expira-
tory volume in 1 s (FEV1): forced vital capacity (FVC),70%, was
present in 83% of patients. FEV1 was ,80% predicted value in
84% of patients, and ,50% pred value in 63% of patients. Gas
exchange was severely impaired, with a mean single-breath
diffusing capacity of the lung for carbon monoxide (DL,CO) of
29¡13% pred value. When compared with LAM patients with-
out PH, patients with LAM and PH had more severe airflow
obstruction, lower diffusion capacity for CO, more severe hypo-
xaemia and impairment of exercise capacity.
Haemodynamics
Table 3 reports the results of RHC. Mean PAP was 32¡6 mmHg,
and pulmonary vascular resistance (PVR) was 376¡184
dyn?s?cm-5. None of the eight patients tested were acutely
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FIGURE 1. The correlation between systolic pulmonary artery pressure (PAP), estimated at echocardiography and a) systolic PAP measured at right heart catheterisation
(RHC) or b) measured mean PAP. c) Accuracy of estimated systolic PAP compared with systolic PAP measured by RHC in relation to PAP. -----: -10 mmHg and +10 mmHg,
respectively.
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vasoreactive to inhaled NO. Mean PAP was.35 mmHg in four
patients with definite LAM (20%), two of whom had normal
FEV1, and one with mean PAP of 40 mmHg and FEV1 of 52%
pred had a history of anorexigen intake. Mean PAP was .40
mmHg in one patient (5%) who had normal FEV1.
Significant correlations were observed between haemody-
namic parameters and pulmonary function (table S1, fig. 2),
especially between PVR and FEV1 and DL,CO and the transfer
coefficient for the lung for carbon monoxide (KCO), but not
with arterial oxygen tension (Pa,O2) or arterial oxygen satura-
tion measured by pulse oximetry (Sp,O2) at the end of the
6MWT. Mean PAP correlated with estimated systolic PAP at
echocardiography (r50.583, p50.063).
Outcome and survival analysis
95% of patients received long-term supplemental nasal oxygen
therapy; 30% received diuretics and 25% were given oral
anticoagulant therapy, for PH.
Six (30%) out of the 20 patients received first-line therapy for
PAH with dual endothelin receptor antagonist (bosentan n55) or
phosphodiesterase type-5 inhibitors (sildenafil n51) with no
concomitant change in supplemental oxygen therapy. No patient
was administered prostacyclin derivatives. In this subgroup
of six treated patients, no statistically significant difference
was observed on NYHA functional class (p50.987), 6MWD
(p50.983), cardiac index (p50.786), FEV1 (p50.530), Pa,O2
(p50.179) or Sp,O2 (p50.880) between the evaluation before
PAH therapy and the last evaluation on therapy (fig. 3). Right
heart cavities were dilated in three out of six patients, with no
change upon PH therapy. Mean PAP decreased significantly in
the six treated patients with PAH therapy from 33¡9 mmHg to
24¡10 mmHg (mean difference 9 mmHg, 95% CI 5–14; p50.003)
after a median of 38 months (interquartile range (IQR) 14.5–
34 months). PVR declined in the six treated patients from
481¡188 dyn?s?cm-5 to 280¡79 dyn?s?cm-5 (mean difference
201 dyn.s.cm-5, 95% CI 18–384; p50.037). Overall, an improve-
ment (predefined by NYHA functional class reduction and/or a
TABLE 1 Characteristics, clinical manifestations and pulmonary function tests at diagnosis of pre-capillary pulmonary
hypertension (PH) in 20 patients with lymphangioleiomyomatosis (LAM) compared with 72 patients with LAM
without PH
Variables LAM with PH Control LAM without PH p-value
Patients 20 72
Age mean yrs 49¡12 (33–73) 44¡19 (33–73) 0.362
Post-menopausal 10 (50) 30 (71) 0.612
Smoker
Current
Ex-smoker
Never smoked
0
5
15
2
22
48
0.644
LAM diagnosis
Definite
Probable
19
1
66
6
1
Lung biopsy with LAM 13 (65) 41 (57) 0.612
Tuberous sclerosis complex 2 (10) 12 (17) 0.726
Renal angiomyolipoma 9 (45) 32 (44) 1
History of pneumothorax# 8 (40) 36 (50) 0.460
History of chylothorax" 5 (25) 13 (18) 0.529
History of chylous ascites 2 (10) 5 (7) 0.643
Lymphangioleiomyoma 3 (15) 20 (28) 0.382
Lymph node involvement (pathology) 1 (5) 6 (8) 1
Dyspnoea 20 (100) 53 (74) 0.009
NYHA functional class
I
II
III
IV
0
1
10
9
11
22
18
4
,0.001
Haemoptysis 2 (10) 0 (0) 0.045
Finger clubbing 2 (10) NA NA
History of right heart failure or lower limb oedema 4 (20) 0 (0) 0.002
Syncope at exercise 0 (0) 0 (0) 1
Body mass index 21¡3 (14–30) 22¡3 (16–37) 0.212
Data are presented as n, mean¡SD (range) or n (%), unless otherwise stated. NYHA: New York Heart Association; NA: not available. #: bilateral in seven out of eight
cases; ": six other patients had a history of pleural effusion not otherwise specified.
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20% increase in 6MWD and/or a 20% decrease in PVR with 20%
diminution of mean PAP) was seen in the five patients who
received bosentan, but not in the patient given sildenafil.
In addition, one patient was treated with sirolimus (but no
PAH treatment) for LAM progression and had a follow-up
evaluation after 10 months of therapy; NYHA functional class
had changed from IV to III, 6MWD from 330 m (Sp,O2 of 84%)
to 350 m (SpO2 of 90%), FEV1 from 27% to 53% pred, FVC from
63% to 102%, mean PAP from 35 mmHg to 23 mmHg, PVR
from 168 dyn?s?cm-5 to 178 dyn?s?cm-5, and cardiac index from
5.2 L?min-1?m-2 to 3.9 L?min-1?m-2.
Overall, the study subjects were followed for a mean of
2.5¡2.1 yrs from the diagnosis of PH. No patient was lost to
follow-up. At the end of follow-up, one patient had died from
cardiac arrest and five patients had undergone single or double
lung transplantation (three and two patients, respectively). The
overall probability of survival was 94% at 1 yr, 94% at 2 yrs,
and 78% at 3 yrs (fig. 4). The transplant-free probability of
survival was 87% at 1 yr, 78% at 2 yrs, and 56% at 3 yrs.
Pathology assessment of explanted lungs
Pathological assessment of explanted lungs in five patients
demonstrated pronounced vascular remodelling, with involve-
ment of the pulmonary arterial walls by characteristic LAM
cells (so-called PEComa cells) (table 4, fig. 5). Cells within the
remodelled pulmonary arteries were further characterised as
LAM/PEComa cells by positive HMB45 immunostaining in
3/3 cases available. As expected, LAM/PEComa cells were
also observed along the edges of the lung cysts, bronchioles,
and pulmonary lymphatics.
DISCUSSION
The present study is the first to report the haemodynamic
evaluation of LAM patients with pre-capillary PH confirmed
by RHC, the gold standard for PH diagnosis [23].
The main findings were as follows: 1) PH was generally of only
mild haemodynamic severity, with mean PAP of 32¡6 mmHg
and PVR of 376¡184 dyn?s?cm-5, and only 20% of patients had
mean PAP .35 mmHg (out-of-proportion PH); 2) PH was
diagnosed after a mean of 9.2¡9.8 yrs following the LAM
diagnosis in patients with mean FEV1 of 46.4¡26% pred value,
chronic hypoxaemia (mean Pa,O2 of 7.4¡1.1 kPa), and moderate-
to-severe exercise intolerance as shown by mean 6mwd of
340 ¡ 84 m with mean Sp,O2 of 81.3¡9.3% at the end of the
test; 3) patients with PH had more severe dyspnoea, airflow
TABLE 2 Pulmonary functions and 6-min walking test (6MWT) in patients with lymphangioleiomyomatosis (LAM) and pulmonary
hypertension (PH) compared with 72 patients with LAM without PH
Variable Patients LAM with PH Control LAM without PH p-value
FVC % pred 18 76¡28 (27–121) 88¡25 (30–145) 0.08
FEV1 % pred
Prebronchodilator 19 42¡24 (13–96) 63¡25 (16–129) 0.002
Postbronchodilator 19 46¡26 (13–96) NA NA
FEV1/FVC % pred 18 47¡15 (22–75) 60¡16 (24–95) 0.003
TLC % pred 20 104¡16 (77–143) 109 ¡23 (51–169) 0.404
RV % pred 20 162¡52 (63–243) 143¡58 (65–309) 0.461
DL,CO % pred 18 29¡13 (14–57) 50¡25 (15–111) 0.002
KCO % pred 13 35¡14 (19–69) 57¡22 (15–93) 0.002
Pa,O2 at rest kPa 17 7.4¡1.1 (5.5–9.5) 10.1¡1.9 (6.7–14.5) ,0.001
Pa,CO2 at rest kPa 18 4.8¡0.5 (3.9–5.9) 4.7¡0.6 (3.7–6.7) 0.188
6MWD m 18 340¡84 (200–475) 474¡144 (110–770) 0.001
Sp,O2 % at end of 6MWT 18 81¡9 (57–91) 88¡8 (62–99) 0.009
Sp,O2 % decrease during 6MWT 18 -10¡8 (-28–0) -8¡8 (-36–2) 0.189
Data are presented as n or mean¡SD (range) unless otherwise stated. FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in 1 s; TLC: total
lung capacity; RV: residual volume; DL,CO: diffusing capacity of the lungs for carbon monoxide; KCO: transfer coefficient for the lung for carbon monoxide; Pa,O2: arterial
oxygen tension; Pa,CO2: arterial carbon dioxide tension; 6MWD: 6-min walking distance; Sp,O2: arterial oxygen saturation measured by pulse oximetry; NA: not available.
TABLE 3 Haemodynamic data at the time of pulmonary
hypertension diagnosis
Variable Patients
Mean PAP, mmHg 20 32¡6 (25–51)
Diastolic PAP, mmHg 19 22¡5 (12–30)
Systolic PAP, mmHg 19 48¡11 (38–84)
Cardiac output, L?min-1 20 5.4¡1.9 (3.1–9.5)
Cardiac index, L?min-1?m-2 20 3.4¡1.1 (2.1–5.7)
PVR dyn?s?cm-5 20 376¡184 (118–776)
PVR index dyn?s?cm-5?m-2 20 572¡307 (190–1433)
Right atrial pressure mmHg 19 7¡3 (0–12)
Capillary wedge pressure mmHg 19 10¡3 (4–15)
Sv,O2 % 12 69¡7 (59–80)
Data are presented as n or mean¡ SD (range). PAP: pulmonary arterial
pressure; PVR: pulmonary vascular resistance; Sv,O2: mixed venous oxygen
saturation.
PULMONARY HYPERTENSION AND LAM V. COTTIN ET AL.
634 VOLUME 40 NUMBER 3 EUROPEAN RESPIRATORY JOURNAL
obstruction, hypoxaemia, and impairment of exercise capacity
than patients with LAM but without PH; 4) haemodynamic
parameters correlated with pulmonary function and especially
with FEV1, DL,CO, and KCO; 5) significant remodelling of the
pulmonary arteries was observed with involvement by HMB45
positive LAM/PEComa cells; 6) the overall probability of
survival was 94% at 2 yrs, and transplant-free survival was
78% at 2 yrs; 7) off-label oral PAH therapy in a subgroup of
patients was associated with a significant decrease in mean PAP
and PVR without a significant difference in exercise capacity or
dyspnoea.
Impairment of pulmonary function in our study population was
more severe than in most recent series of LAM patients, who had
mean FEV1 of 65% to 75% pred at the time of diagnosis [10, 12,
13, 30, 31]. Patients with PH had more airflow obstruction than
LAM patients without PH, indicating that PH generally occurs in
subjects with more advanced pulmonary disease. Consistent
with this hypothesis, LAM diagnosis preceded PH diagnosis by
almost a decade, and five patients (25%) underwent lung
transplantation within 2 yrs after being diagnosed with PH.
However, unexpected correlations were found between lung
function and haemodynamic parameters, with greater mean
PAP, superior PVR, and lower cardiac index in patients with
improved preserved FEV1 and DL,CO, indicating that PH may
progress independently of parenchymal lung disease. In
contrast, systolic or mean PAP correlates inversely with DL,CO
in idiopathic pulmonary fibrosis patients, although it correlates
poorly with lung volume [32–35]. Sp,O2 was significantly
decreased during exercise, and most LAM and PH patients
required long-term oxygen therapy. However, mean PAP did
not correlate with Pa,O2 at rest, consistent with a previous
observation that PH (during exercise) cannot be predicted from
resting pulmonary function testing [19]. Although our small
sample size prevents firm conclusions, our study indicates that
PH can occur in patients with mild-to-severe lung function
impairment and may reflect intrinsic vasculopathy in an
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unknown proportion of patients, as suggested by pathological
findings in five patients and earlier descriptions of the
involvement of pulmonary arteries by cell proliferation in
LAM [36, 37]. It is conceivable that mTOR activation in LAM
may contribute to PH in patients with LAM [21], as in patients
with neurofibromatosis type 1 [38].
The mean PAP in our patients (32¡6 mmHg) was strikingly
similar to that reported by REYNAUD-GAUBERT et al. [7] (33¡8
mmHg) in nine patients evaluated for lung transplantation, and
higher than that observed by HARARI et al. [16] (26.0¡2.5 mmHg)
in six patients also evaluated for lung transplantation, but
not included in the present series. PH in the context of chronic
parenchymal lung disease is usually mild or moderate (i.e. with
mean PAP ,35–40 mmHg). However, subgroups of patients
with chronic obstructive pulmonary disease (COPD) [39–41],
idiopathic pulmonary fibrosis [42], or combined pulmonary
fibrosis and emphysema syndrome [43] have severe ‘‘out-of-
proportion’’ pre-capillary PH, usually defined by mean PAP
.35–40 mmHg [17, 39]. These subjects are prone to right heart
failure and may share similarities with idiopathic PAH [43, 44].
Only 20% of patients in the present study had mean PAP
.35 mmHg with 5% disclosing mean PAP .40 mmHg, ful-
filling this definition. Interestingly, two of these patients had
normal FEV1 with PH and were thus ‘‘out-of-proportion’’. The
highest mean PAP recorded in our study was 51 mmHg, and
47 mmHg in that of REYNAUD-GAUBERT et al. [7]. The mean
haemodynamic profile of LAM patients in the present series was
much less severe than that of PAH patients in the national
French registry (with a higher PVR index of 1,640 dyn?s?cm-5?m-2
and cardiac index of 2.5 L?min-1?m-2) [22]. It was also less severe
than in patients with pre-capillary PH and pulmonary Langer-
hans cell histiocytosis [45, 46], combined pulmonary fibrosis and
emphysema [43], or sarcoidosis [47], and somewhat comparable
to that of PH associated with idiopathic pulmonary fibrosis
[32, 35, 42]. However, although mean PAP was only mildly
elevated, some patients with mild lung-function impairment had
severe and ‘‘out-of-proportion’’ PH.
The clinical relevance of PH in patients with LAM is currently
unknown. In a study by TAVEIRA-DASILVA et al. [19], peak
exercise PAP correlated negatively with Sp,O2, indicating that
PH may contribute to exercise-induced hypoxaemia and
exercise limitation; increased systolic PAP was observed during
low-level exercise corresponding to daily living activities.
Predictors of a more severe prognosis could not be evaluated
in the present series, because of the small sample size. How-
ever, LAM patients with PH had lower DL,CO, more severe
hypoxaemia, and impaired exercise capacity when compared
with LAM patients without PH, suggesting that a low diffusion
capacity in LAM should prompt to perform an echocardiogra-
phy. A significant proportion of our PH and LAM patients died
or underwent lung transplantation within 2 yrs of PH diagnosis.
Although no formal survival comparison was made to a group
of LAM patients without PH, the present finding questions
whether PH might have prognostic significance in LAM, similar
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FIGURE 3. Outcome of six patients who received
bosentan or sildenafil. NYHA FC: New York Heart
Association Functional Class; 6MWD: 6-min walking
distance; PAP: pulmonary arterial pressure; PVR:
pulmonary vascular resistance; FEV1: forced expira-
tory volume in 1 s; Sp,O2: arterial oxygen saturation
measured by pulse oximetry; (room air); Pa,O2: arterial
oxygen tension (room air). *: p,0.05 versus baseline.
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to what has been reported in idiopathic pulmonary fibrosis
[42, 48], COPD [49], and combined pulmonary fibrosis and
emphysema [50, 51]. The 10-yr survival rate of patients with
LAM has been reported to 71%, 79%, and 91% from the time of
diagnosis in large series [10, 11, 52]. Thus, the potential impact of
PH on long-term survival in LAM deserves further analysis in
prospective studies.
The potential benefit of PAH-specific therapy is not known in
PH patients with associated pulmonary parenchymal disor-
ders, as these drugs have not been approved in this setting. It is
unlikely that the rare occurrence of PH in LAM (an ‘‘orphan’’
disease) will be investigated in a dedicated clinical trial. A
minority of patients in the present series were treated off-label
on an individual basis, providing some interesting preliminary
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FIGURE 4. Transplant-free and overall survival in patients with lymphangioleiomyomatosis and pulmonary hypertension.
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FIGURE 5. Pathological assessments of lungs at the time of transplantation in three patients with pulmonary lymphangioleiomyomatosis (LAM). a–d) Haematoxylin-
eosin staining in one patient. a) Two bronchioles (#) and their adjacent pulmonary arteries (arrows). Both structures show remodelling; the bronchioles are directly involved
with characteristic LAM/ perivascular epithelioid cells (PEComa)-cell proliferation (arrowheads), while pulmonary arteries display intimal fibrosis and some minor LAM/
PEComa involvement. b) Two pulmonary veins with paucicellular collagen-rich intimal fibrosis (arrows). Note the two LAM/PEComa-foci (arrowheads) surrounding the blood
vessels. c) Two pulmonary arteries displaying medial hypertrophy and intimal fibrosis (arrows) and adjacent bronchiole (#). d) A pulmonary artery showing tortuosity and
intimal fibrosis. Note involvement of the artery with PEComa cell proliferation at the periphery of the vessel (arrowheads). e) Immunohistochemical staining for HMB45
demonstrating a pulmonary artery with HMB-45+ cells within the remodelled vessel-wall. f) Immunohistochemical staining for HMB45 showing a small arteriole or venule
presenting muscularisation and involvement of HMB-45+ LAM cells.
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information on the efficacy and safety of PAH therapy in this
condition. PAH treatment with bosentan or sildenafil was well
tolerated, especially since gas exchange was not significantly
impaired as has been observed in some COPD and PH pa-
tients [53]. Although involvement of pulmonary veinules was
observed pathologically, pulmonary oedema was not observed at
initiation of PH therapy. Haemodynamics improved significantly
with a 28% decrease in mean PAP and a 42% reduction of PVR,
but no significant effect of therapy was apparent on dyspnoea
or exercise capacity (although such analysis was underpow-
ered). Sirolimus, which has proven beneficial in lung function
and clinically-relevant parameters [5], should be considered
in LAM patients with progressive disease. The present study
did not allow us to evaluate whether sirolimus may also
contribute to improvement in PH patients with LAM. Nasal
oxygen supplementation should be considered whenever appro-
priate [6]. Younger LAM patients should be evaluated early for
lung transplantation, which remains the issue in advanced
disease [6–9].
This study sheds light on the utility of non-invasive methods
screening for PH in LAM patients. No patients tested in the
present series had elevated serum BNP levels, and only 35% had
dilated right heart cavities on echocardiography. All patients
with mean PAP.25 mmHg at RHC had estimated systolic PAP
of o40 mmHg based on systolic regurgitation of the tricuspid
valve. Conversely, patients who eventually manifested mean
PAP between 20 mmHg and 25 mmHg had estimated systolic
PAP f40 mmHg on echocardiography. Although this study
was not designed to evaluate the diagnostic value of echocar-
diography, we suggest that LAM patients with estimated
systolic PAP o40 mmHg on echocardiography undergo RHC.
It is known that echocardiography lacks specificity and accuracy
in patients with advanced lung disease, including emphysema
[54] and idiopathic pulmonary fibrosis [55, 56]. No patients in
the present study had post-capillary PH. Although the current
study was not designed to evaluate the prevalence of PH, a
conservative 7% was estimated for PH prevalence in LAM
patients, consistent with a previous similar assessment based on
echocardiography [19].
Our investigation has some limitations, especially its observa-
tional and uncontrolled design owing to the rarity of this
condition. However, LAM cases were prospectively included
in the GERM‘‘O’’P registry, and haemodynamic data were
collected prospectively in the setting of the French national PH
registry. Haemodynamic and pulmonary functions were not
evaluated during exercise. As indications for echocardiogra-
phy and treatment were left to the physicians’ discretion, the
data presented here are potentially subject to bias and should
not be interpreted as proper evaluation of therapeutic efficacy.
However, data on haemodynamic parameters and survival
were unlikely to be affected by the study design.
In conclusion, PH may occur in a small subset of LAM patients
after a mean of 9 yrs after diagnosis. It can affect LAM patients
with mildly to severely-impaired lung function, most of them
requiring long-term oxygen therapy. However, mean PAP and
PVR did not correlate with Pa,O2, indicating that factors other
than hypoxia, and especially LAM/PEComa cell vasculopathy,
may contribute to PH. Whether PAH-specific therapy may be
beneficial in LAM patients with PH deserves further study.
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